Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026
Same author

Patient-reported outcome measures used in studies of palliative surgery in cancer care: a scoping review.

Annals of palliative medicine·2026
Same author

Reframing High-Risk Operation as a Time-Limited Trial.

Journal of the American College of Surgeons·2026
Same author

Bioengineered systems to exploit tumor microenvironment metabolism.

Trends in cancer·2026
Same author

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.

The Lancet. Oncology·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.9K

Retroperitoneal Sarcoma (RPS): A Systematic Review.

Ilaria Caturegli1, Elizabeth J Lilley2, Mark Fairweather2

  • 1Brigham and Women's Hospital, Boston, MA, USA. icaturegli@bwh.harvard.edu.

Current Oncology Reports
|June 4, 2025
PubMed
Summary
This summary is machine-generated.

Retroperitoneal sarcomas (RPS) are rare cancers. While surgery is key, new treatments are emerging, and their effectiveness depends on the specific tumor type.

Keywords:
LeiomyosarcomaLiposarcomaRadiation therapyRetroperitoneal sarcoma

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
03:55

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Published on: December 29, 2023

646

Related Experiment Videos

Last Updated: Sep 19, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.9K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
03:55

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Published on: December 29, 2023

646

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Retroperitoneal sarcomas (RPS) are rare malignancies with diverse histologic subtypes.
  • Surgical resection is the primary curative treatment for non-metastatic RPS, with extent varying by histology.
  • Current neoadjuvant therapies show limited efficacy, with benefits contingent on specific tumor types, regimens, and timing.

Purpose of the Study:

  • To review the current work-up and management strategies for retroperitoneal sarcomas.
  • To discuss recent advances and emerging therapeutics in the field of RPS.

Main Methods:

  • Literature review of studies on retroperitoneal sarcomas.
  • Analysis of current treatment guidelines and recent clinical findings.
  • Synthesis of information on diagnostic work-up, surgical management, and novel therapies.

Main Results:

  • Neoadjuvant therapies have shown limited response and efficacy in RPS.
  • Treatment benefit, regimen, and timing of neoadjuvant therapies are histology-dependent.
  • Innovative therapeutic approaches are under investigation and show promise.

Conclusions:

  • Management of RPS requires a multidisciplinary approach tailored to histologic type.
  • Advances in understanding RPS biology are paving the way for more effective treatments.
  • Further research into novel therapeutics is crucial for improving patient outcomes.